Inhibitors of HIV-1 protease: A major success of structure-assisted drug design

Annual Review of Biophysics and Biomolecular Structure

Volumn 27, Issue , 1998, Pages 249-284

  Wlodawer, Alexander ^a   Vondrasek, Jiri ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

Author keywords

AIDS; Drug design; Inhibitors; Protease

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; A 74704; A 75925; A 77003; A 80987; AG 1002; AG 1004; AMPRENAVIR; INDINAVIR; KYNOSTATIN 272; L 682679; L 685434; MOZENAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SD 146; SD 152; TIPRANAVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG RESISTANCE; DRUG SYNTHESIS; ENZYME ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; REVIEW;

BINDING SITES; BIOPHYSICS; DRUG DESIGN; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MODELS, MOLECULAR; NELFINAVIR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN STRUCTURE, SECONDARY; QUANTUM THEORY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031804609     PISSN: 10568700     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.biophys.27.1.249     Document Type: Review

References (11)

1. Ala PJ, Huston EE, Klabe RM, McCabe DD, Duke JL, et al. 1997. Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry 36:1573-80
2. Appelt K. 1993. Crystal structures of HIV-1 protease-inhibitor complexes. Perspect. Drug Discovery Des. 1:23-48
3. Appelt K, Bacquet RJ, Bartlett CA, Booth CL, Freer ST, et al. 1991. Design of enzyme inhibitors using iterative protein crystallographic analysis. J. Med. Chem. 34:1925-34
4. Backbro K, Lowgren S, Osterlund K, Atepo J, Unge T, et al. 1997. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor. J. Med. Chem. 40:898-902
5. Bhat TN, Baldwin ET, Liu B, Cheng YS, Erickson JW. 1994. Crystal structure of a tethered dimer of HIV-1 proteinase complexed with an inhibitor. Nat. Struct. Biol. 1:552-56
6. Boucher C. 1996. Rational approaches to resistance: using saquinavir. AIDS 10 Suppl. 1:S15-19
7. Bujacz G, Alexandratos J, Zhou-Liu Q, Clement-Mella C, Wlodawer A. 1996. The catalytic domain of human inmmunodeficiency virus integrase: ordered active site in the F185H mutant. FEBS Lett. 398:175-8
8. Bujacz G, Jaskolski M, Alexandratos J, Wlodawer A, Merkel G, et al. 1995. High resolution structure of the catalytic domain of the avian sarcoma virus integrase. J Mol. Biol. 253:333-46
9. Bujacz G, Jaskolski M, Alexandratos J, Wlodawer A, Merkel G, et al. 1996. The catalytic domain of avian sarcoma virus integrase: conformation of the active-site residues in the presence of divalent cations. Structure 4:89-96
10. Caflisch A, Niederer P, Antiker M. 1992. Monte Carlo docking of oligopeptides to proteins: proteins. Struct. Fund. Genet. 13:223-30
11. Chen X, Tropsha A. 1995. Relative binding free energies of peptide inhibitors of HIV-1 protease: the influence of the active site protonation state. J. Med. Chem. 38:42-48